title: Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey.
abstract: Long used in established industrialized nations to treat patients with haemophilia and inhibitors, factor eight inhibitor bypassing activity (FEIBA) has, in recent years, been introduced into more geographically diverse settings. Data are needed on how successfully FEIBA therapy has been implemented in new regions. To determine the efficacy and safety of FEIBA for the treatment of acute bleeding and surgical haemostasis in a newly industrialized country. A multicentre registry of haemophilia A patients with inhibitors receiving FEIBA treatment was established in Turkey. With a standardized case report form, data were collected retrospectively on: patient demographics; characteristics of acute bleeding episodes and surgical interventions; FEIBA regimen; and treatment outcomes. Thirty-seven patients received a total of 112 FEIBA treatment courses, 90 for acute bleeding and 22 for surgical haemostasis. The median FEIBA dose per infusion for acute bleeding was 50 IU kg(-1), and for surgery was 100 IU kg(-1). For both acute joint and muscle/soft tissue bleeding and in surgery, haemostasis was attained in a median of two FEIBA infusions. FEIBA was judged effective in 92% of treatment courses for acute bleeding, with a 95% confidence interval (CI) of 85-97%. Rates of haemostatic efficacy did not differ significantly between anatomical sites of acute bleeding. The haemostatic efficacy rate of FEIBA in surgery was 86% (CI, 65-97%). No thromboembolic complications or other adverse events occurred during any treatment course. FEIBA has been successfully integrated into clinical practice in Turkey, with rates of haemostatic efficacy comparable to those reported in countries with a longer history of FEIBA usage.
authors: Institute of Oncology, Istanbul University, Istanbul, Turkey. bzulfikar@superonline.com
authors: B
authors: B
authors: Zülfikar
authors: G
authors: G
authors: Aydogan
authors: Z
authors: Z
authors: Salcioglu
authors: A F
authors: AF
authors: Oner
authors: K
authors: K
authors: Kavakli
authors: T
authors: T
authors: Gursel
authors: H
authors: H
authors: Zülfikar
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D003029:Coagulants / Q000009:adverse effects / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology; D005260:Female; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy*; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D013514:Surgical Procedures, Operative / Q000379:methods; D014421:Turkey; D055815:Young Adult
chemical_list: D001779:Blood Coagulation Factors; D003029:Coagulants; D005169:Factor VIII; C065655:anti-inhibitor coagulant complex